2-weekly docetaxel: issues for clinical practice

Cancer Biol Ther. 2015;16(1):17-8. doi: 10.4161/15384047.2014.987534.


In the phase III trial comparing 2 docetaxel schedules (3-weekly versus 2-weekly) as first-line chemotherapy for CRPC, recently published in The Lancet Oncology, fewer serious adverse events, particularly hematologic toxicities, and longer times on treatment, in favor of the 2-weekly regimen are reported. (1,2,3.)

Keywords: 3-weekly schedule; doxetaxel; mCRPC.

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Docetaxel
  • Drug Administration Schedule
  • Humans
  • Male
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Taxoids / administration & dosage*


  • Antineoplastic Agents
  • Taxoids
  • Docetaxel